Treatment Response Rates High for Seniors With Hep C Infection
FRIDAY, Nov. 15, 2019 -- For patients with chronic hepatitis C infection, sustained viral response (SVR) rates are similar for those aged 65 years and older and those younger than 65, accordi
FDA Approves Fetroja
FDA Approves Fetroja (cefiderocol) for the Treatment of Complicated Urinary Tract Infections
November 14, 2019 -- The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of p
FDA Approves Brukinsa
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical
CA125 Can Detect Ovarian Cancer in General Practice
FRIDAY, Nov. 8, 2019 -- Cancer antigen 125 (CA125) can predict ovarian cancer in general practice, and elevated CA125 can also indicate an increased risk for nonovarian cancer, according to two studies
FDA Approves Reblozyl
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:
FDA Approves Ziextenzo
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) app